CD8A and neoplasm: Immunohistochemical experiments demonstrated that targeting MS4A4A, in combination with PD‐1 antibody treatment, substantially enhanced the infiltration of CD3+ and CD8+ T cells in tumor‐bearing mice (Figure S9).